Reversible acute gastrointestinal syndrome associated with active systemic lupus erythematosus in patients admitted to hospital.
Patients with systemic lupus erythematosus (SLE) frequently have gastrointestinal (GI) symptoms. These are usually self-limiting and related to treatment side-effects or concurrent illness. However, abdominal pain may be due to bowel ischaemia which can lead to infarction and perforation. The likelihood of these serious events is increased in individuals with pain severe enough to require assessment in hospital or a SLEDAI score > 5. This paper describes a group of patients with active SLE and GI symptoms severe enough to require admission to hospital using a retrospective review of 52 SLE patients admitted to hospital with acute abdominal symptoms. The results showed that abdominal pain (87%), vomiting (82%) and diarrhoea (67%) had been present for a mean of 4.4 +/- 6.5 days and SLEDAI score was > or = 4 in 83% of patients. CT scanning showed evidence of serositis and bowel involvement in 63% of patients who underwent this investigation. Intravenous (iv) fluids were used in 87%, parenteral steroids in 90% and iv cyclophosphamide in 31%. Most (n = 51) were discharged well. Recurrence of GI symptoms occurred in 12 patients. The conclusions are that active SLE may manifest as an acute gastrointestinal syndrome. Early diagnosis, bowel rest, supportive medical therapy and treatment with corticosteroids and/or immunosupressives can result in a good outcome.
Lian
T Y
TY
Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore. tsui_yee_lian@ttsh.com.sg
Edwards
C J
CJ
Chan
S P
SP
Chng
H H
HH
D015746:Abdominal Pain / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy; D000208:Acute Disease; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005767:Gastrointestinal Diseases / Q000000981:diagnostic imaging / Q000209:etiology* / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000000981:diagnostic imaging / Q000209:etiology* / Q000401:mortality / Q000628:therapy*; D008231:Lymphopenia / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D010343:Patient Admission; D011860:Radiography, Abdominal; D012709:Serum Albumin / Q000378:metabolism; D018434:Sickness Impact Profile; D012846:Singapore; D013223:Statistics as Topic; D016019:Survival Analysis; D013577:Syndrome; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D015415:Biomarkers; D007166:Immunosuppressive Agents; D012709:Serum Albumin; D003520:Cyclophosphamide; D002097:C-Reactive Protein; D008775:Methylprednisolone